- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ICYMI: Highlights From ESMO Congress 2023
Our most-read coverage from the 2023 European Society for Medical Oncology (ESMO) Congress included potentially practice-changing findings across a range of cancer types, including lung cancer, breast cancer, and urothelial carcinoma.
Our most-read coverage from the 2023 European Society for Medical Oncology (ESMO) Congress included potentially practice-changing findings across a range of cancer types, including lung cancer, breast cancer, and urothelial carcinoma.
Here are the ESMO 2023 conference highlights. Click here to catch up on all of our coverage from the conference.
5. TROPION-Breast01, TROPION-Lung01 Demonstrate PFS Benefit of Datopotamab Deruxtecan in Metastatic Breast Cancer, NSCLC
Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) compared with standard of care in both non–small cell lung cancer (NSCLC) and hormone receptor–positive/HER2-negative breast cancer, according to findings presented at ESMO Congress 2023. In both presentations, trial investigators noted less toxicity with datopotamab deruxtecan compared with control interventions.
4. Dr Thomas Powles Discusses Impact of EV+P Therapy on Urothelial Carcinoma Treatment
Findings from the EV-302/KEYNOTE-A39 trial, presented at ESMO Congress 2023, suggest a new standard of care may be on the horizon in urothelial carcinoma for the first time in decades. Lead investigator Thomas Powles, MD, MBBS, MRCP, discussed the findings and the unmet need for therapies in metastatic urothelial carcinoma in an interview with The American Journal of Managed Care®.
3. Trastuzumab Deruxtecan Demonstrates Efficacy Reducing Brain Metastases in HER2m NSCLC
Results presented at ESMO Congress 2023 demonstrated that the presence of brain metastases (BM) did not affect response to treatment with trastuzumab deruxtecan among patients with metastatic HER2 (ERBB2)-mutant (HER2m) NSCLC. A significant proportion of patients with HER2m NSCLC have BM at diagnosis, and post hoc pooled analyses of trastuzumab deruxtecan efficacy and safety from DESTINY-Lung01 and DESTINY-Lung02 suggest similar response rates regardless of BM status.
2. Amivantamab Plus Lazertinib Improved PFS for EGFR-Mutated Advanced NSCLC
MARIPOSA and MARIPOSA-2 results showed improved PFS with amivantamab plus lazertinib vs osimertinib in the first-line setting and after progression on osimertinib in EGFR-mutated advanced NSCLC. In the MARIPOSA trial, the combination regimen reduced risk of progression or death by 30% vs osimertinib, and MARIPOSA-2 found that amivantamab plus chemotherapy and amivantamab plus chemotherapy and lazertinib also improved progression-free survival (PFS) over chemotherapy alone after progression on osimertinib.
1. First in Decades: Enfortumab Vedotin + Pembrolizumab Beats Chemo in First-Line Metastatic Urothelial Cancer
Enfortumab vedotin plus pembrolizumab significantly improved outcomes compared with standard-of-care chemotherapy in patients with locally advanced metastatic urothelial cancer, marking the first time in decades that a new treatment outperformed chemotherapy in this disease setting. Both PFS and overall survival were significantly prolonged in the enfortumab vedotin plus pembrolizumab, suggesting this regimen may be a new standard of care for advanced metastatic urothelial cancer.
Finding the Right Biomarker Is Key to the TIGIT Puzzle, Experts Say
May 12th 2025Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising therapeutic target. But investigators involved in TIGIT studies say the problem is finding the right biomarker.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Community Oncology Reacts to Trump's Drug Pricing Executive Order
May 2nd 2025An executive order signed on Tuesday, March 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.
Read More
